NEWHALL CHARLES W III — SEC Form 4 filings
SEC reporting owner CIK 1005544. 12 Form 4 filings on record with FilingPulse; latest filed 2026-02-25.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-02-26 to 2026-02-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 5 filings — 41,700 shares, $1,927,038 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 23,800 shares @ $50.73 ($1,207,374) in SUPERNUS PHARMACEUTICALS, INC., filed 2025-10-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Director | 12 | — | 6 legs · 41,700 sh · $1,927,038 | 16 |
Form 4 filings — NEWHALL CHARLES W III
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-25 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 4,475 @ $0 · Disposition to issuer (D): 4,475 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 2,989 (derivative) @ $0 · Grant/award (A): 4,977 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 15,000 @ $12.98 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-10-10 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Sale (S): 23,800 @ $50.73 · Sale (S): 1,200 @ $51.55 | EDGAR |
| 2025-08-29 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Sale (S): 3,588 @ $45.01 | EDGAR |
| 2025-08-27 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Sale (S): 1,000 @ $45 | EDGAR |
| 2025-08-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Sale (S): 1,412 @ $45 | EDGAR |
| 2025-02-24 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 5,369 @ $0 · Disposition to issuer (D): 5,369 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 7,296 (derivative) @ $0 · Grant/award (A): 4,475 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 20,000 @ $9.13 · Sale (S): 10,700 @ $36.24 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 3,886 @ $0 · Disposition to issuer (D): 3,886 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 8,252 (derivative) @ $0 · Grant/award (A): 5,369 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1005544 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →